Influenza A H7N9 hemagglutinin antigen (HA (H7N9))

The **Influenza A H7N9 hemagglutinin antigen** is the primary envelope glycoprotein found on the surface of H7N9 subtype avian influenza A viruses. Hemagglutinin (HA) is a trimeric molecule responsible for binding to sialic acid-containing receptors on host cells, initiating viral attachment and subsequent membrane fusion required for entry into host cells[2][6][8]. The H7N9 HA has evolved mutations enabling partial human receptor specificity, contributing to its zoonotic potential and pandemic risk[3][5][6][8]. The HA subunit is immunodominant and is the major target for host neutralizing antibodies, monoclonal antibodies, and vaccine design[1][4][7]. The structure of H7N9 HA defines antigenic sites targeted by neutralizing antibodies, and its rapid antigenic evolution complicates control efforts. In summary, **Influenza A H7N9 hemagglutinin antigen** is a critical determinant of host specificity, immune targeting, and pandemic emergence, making it an essential target for therapeutic and prophylactic interventions.

Other names

H7N9 HAInfluenza hemagglutinin H7N9H7 hemagglutinin

Monoclonal antibodies bind hemagglutinin to block receptor binding or fusion, preventing viral entry[1][4] Vaccines elicit neutralizing antibodies targeting HA, providing immunity by blocking virus entry and fusion[7]